Developer docs
API playgroundTry for free, no card

Search company profiles

Zai Lab

Full company profile

uuid0002ccc

Namestring
Zai Lab
Legal namestring
Zai Lab Limited
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Zai Lab Limited is an innovation-driven, commercial-stage biopharmaceutical company founded in 2014 and dual-listed on NASDAQ (ZLAB) and the Hong Kong Stock Exchange (09688.HK), with operational headquarters in Shanghai and Cambridge, Massachusetts. The company discovers, develops, manufactures, and commercializes innovative therapeutics for oncology, immunology, neuroscience, and infectious disease, serving patients and healthcare providers across Greater China with a growing global footprint in the US, Europe, and Asia Pacific.

Zai Lab operates an end-to-end model spanning internal discovery through commercial manufacturing, anchored by a proprietary pipeline that includes the lead DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan (zoci), the IL-13/IL-31R bispecific ZL-1503, the LRRC15 ADC ZL-6201, and the PD-1/IL-12 immunocytokine ZL-1222. Eight products are approved in mainland China, including ZEJULA, OPTUNE GIO, QINLOCK, AUGTYRO, TIVDAK, VYVGART, NUZYRA, XACDURO, and COBENFY, with six on the National Reimbursement Drug List. Manufacturing capabilities include small-molecule facilities in Suzhou (20M hard capsules and 50M tablets annually) and a 4,200 sqm large-molecule facility with GE Flexfactory.

The business model combines in-licensed product commercialization in Greater China with proprietary global pipeline development, generating revenue through product sales supplemented by licensing and partnership arrangements with partners including argenx, Karuna/BMS, Seagen/Pfizer, Vertex, Blueprint Medicines, GSK, Regeneron, BMS, and Novocure. Distribution relies on a specialized disease-franchise commercial organization covering mainland China, Hong Kong, Macau, and Taiwan, with NRDL inclusion, patient assistance programs, and Named Patient Programs driving access. In FY2025, Zai Lab generated $460.2M in revenue (15% YoY growth) with a $175.5M net loss, supported by a $761.3M cash position as of Q1 2026 and approximately 2,100 employees globally.

Short descriptiontext

Zai Lab is a US-China biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative oncology, immunology, neuroscience, and infectious disease therapies for patients across Greater China and select global markets, with eight approved products and six on China's National Reimbursement Drug List.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
innovative biopharmaceuticals, oncology therapeutics, antibody-drug conjugates, Greater China commercialization, clinical drug development
Industry1 code
SECONDARYHLAFAMAE
Molecular Diagnostics & Genomics Laboratories
NAICS code2 codes
  • Medicinal and Botanical Manufacturing325411
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Biopharmaceuticals
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1Product Sales - Oncology
TypeOne Time License
Description

Sales of approved oncology products including ZEJULA (niraparib), OPTUNE GIO, QINLOCK (ripretinib), AUGTYRO (repotrectinib), and TIVDAK (tisotumab vedotin). Zai Lab currently has eight approved products in mainland China.

businesswire.com
2Product Sales - Immunology
TypeOne Time License
Description

Sales of efgartigimod (VYVGART) for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP).

businesswire.com
3Product Sales - Infectious Disease
TypeOne Time License
Description

Sales of NUZYRA (omadacycline) for CABP and ABSSSI, and XACDURO (sulbactam-durlobactam) for HABP/VABP.

businesswire.com
4Product Sales - Neuroscience
TypeOne Time License
Description

Sales of COBENFY (xanomeline and trospium chloride) for schizophrenia following December 2025 NMPA approval.

businesswire.com
5Licensing and Partnership Revenue
TypeLicensing Royalties
Description

Revenue from licensing agreements with partners including Karuna Therapeutics for COBENFY in Greater China, Seagen/Pfizer for TIVDAK, and collaborations with global pharmaceutical companies.

stocktitan.net
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Zai Lab is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative therapeutics for oncology, immunology, neuroscience, and infectious diseases, with eight approved products currently marketed in mainland China and a global pipeline of proprietary candidates. The company combines in-licensed assets from partners such as argenx, Pfizer/Seagen, Karuna/BMS, and Novocure with internally developed antibody-drug conjugates and bispecifics to serve patients and healthcare providers primarily across Greater China, with growing global commercialization plans for the US, Europe, and Asia Pacific.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 45% reduction in risk of death (HR: 0.55) in China subpopulation for TIVDAK vs chemotherapy in recurrent/metastatic cervical cancer
+4 more records
Product and service9 records
1ZEJULA (niraparib)
CategoryOncology therapeutics
Description

PARP inhibitor for first-line maintenance treatment and recurrent maintenance therapy of ovarian cancer, marketed in Greater China.

2OPTUNE GIO (Tumor Treating Fields)
CategoryOncology therapeutics
Description

Tumor Treating Fields delivery system for the treatment of newly diagnosed and recurrent glioblastoma, marketed in Greater China in partnership with Novocure.

3QINLOCK (ripretinib)
CategoryOncology therapeutics
Description

Tyrosine kinase inhibitor for fourth-line treatment of advanced gastrointestinal stromal tumors (GIST), marketed in mainland China.

4AUGTYRO (repotrectinib)
CategoryOncology therapeutics
Description

Tyrosine kinase inhibitor for the treatment of ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive solid tumors, marketed in Greater China.

5TIVDAK (tisotumab vedotin)
CategoryOncology therapeutics
Description

Antibody-drug conjugate (tisotumab vedotin) for adult patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy, marketed in Greater China under license from Seagen/Pfizer.

6VYVGART (efgartigimod)
CategoryImmunology therapeutics
Description

FcRn antagonist (efgartigimod alfa) for adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), marketed in Greater China under partnership with argenx.

7NUZYRA (omadacycline)
CategoryInfectious disease therapeutics
Description

Broad-spectrum antibiotic (omadacycline) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), marketed in mainland China.

8XACDURO (sulbactam-durlobactam)
CategoryInfectious disease therapeutics
Description

Antibiotic combination (sulbactam-durlobactam) for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex, marketed in China.

9COBENFY (xanomeline and trospium chloride)
CategoryNeuroscience therapeutics
Description

M1/M4 muscarinic receptor agonist combination (xanomeline and trospium chloride) for the treatment of schizophrenia in adults, marketed in Greater China under license from Karuna Therapeutics (Bristol-Myers Squibb).

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
1Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-15
Description

Collaboration on DLL3-targeting T-cell engager and ADC combination in small cell lung cancer and other neuroendocrine carcinomas. The collaboration combines Zai Lab's zoci ADC with Boehringer Ingelheim's DLL3-targeting bispecific T-cell engager therapy.

zailaboratory.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Global clinical trial collaboration to evaluate Zai Lab's zocilurtatug pelitecan (DLL3-targeting ADC) in combination with Amgen's IMDELLTRA for extensive-stage small cell lung cancer. Amgen sponsors and leads the Phase 1b study while Zai Lab retains full ownership of its ADC and provides clinical supply.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on povetacicept (BAFF/APRIL) in IgA nephropathy. Zai Lab has exclusive license to develop and commercialize povetacicept in mainland China, Hong Kong, Macau, Taiwan, and Singapore.

Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

China-founded, US-listed biopharmaceutical company with a similar business model combining a profitable China commercial organization (BRUKINSA, etc.) with a global innovation pipeline. Direct peer in oncology-focused biopharma bridging China and global markets.

2HUTCHMED (China) Limited
TypeDirect peer
Description

China-founded, Hong Kong and NASDAQ-listed biopharma developing and commercializing oncology and immunology therapies in China and globally. Comparable in China-focused oncology R&D and commercialization, with overlapping NRDL-listed products and global out-licensing strategy.

TypeDirect peer
Description

China-based biopharma with multiple approved and NRDL-included products in oncology (TYVYT/PD-1, etc.) and growing pipeline. Closely comparable in China commercialization scale, NRDL positioning, and dual China-US R&D footprint.

TypeDirect peer
Description

China-based biopharma developing novel antibodies including PD-1/VEGF bispecifics, with growing commercialization in oncology and immunology. Comparable in novel biologics discovery, China NRDL access, and dual China/global development strategy.

TypeDirect peer
Description

China-based biopharma with an approved PD-1 antibody (toripalimab) and broader oncology pipeline, dual-listed in Hong Kong and on STAR Market. Comparable as a China-headquartered immuno-oncology player with global ambitions.

6Hengrui Medicine
TypeBroad incumbent
Description

China's largest domestic pharmaceutical company with broad oncology, immunology, and other therapeutic portfolios plus extensive NRDL presence. Comparable as a China commercial-scale pharma competitor but with a much broader, established portfolio and generic + innovative mix.

7Hansoh Pharmaceutical Group
TypeBroad incumbent
Description

Large China-headquartered pharmaceutical company with multiple approved innovative drugs across oncology, CNS, and infectious disease. Comparable as a broad Chinese pharma operator with overlapping therapeutic categories and NRDL commercialization experience.

TypeBroad incumbent
Description

Hong Kong-listed Chinese pharmaceutical conglomerate with oncology, neurology, and anti-infective product portfolios plus R&D pipeline. Comparable as a broad incumbent operating in Zai Lab's therapeutic categories and NRDL channels.

9Bristol-Myers Squibb
TypeOthers
Description

Global biopharma and existing Zai Lab partner/seller of in-licensed products (QINLOCK, AUGTYRO, COBENFY via Karuna acquisition). Comparable as a global oncology and immunology player with overlapping therapeutic franchises and pipeline interest in DLL3 and related targets.

TypeOthers
Description

Global biopharma with the competing DLL3-targeted T-cell engager IMDELLTRA, and strategic clinical collaboration partner with Zai Lab on zoci + IMDELLTRA combinations. Comparable as a global oncology innovator with overlapping SCLC pipeline interests and partner-based China market access patterns.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles26 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds14 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors21 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Zai Lab

Biopharmaceuticalszailaboratory.com

Zai Lab is a US-China biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative oncology, immunology, neuroscience, and infectious disease therapies for patients across Greater China and select global markets, with eight approved products and six on China's National Reimbursement Drug List.

What Zai Lab does

Zai Lab Limited is an innovation-driven, commercial-stage biopharmaceutical company founded in 2014 and dual-listed on NASDAQ (ZLAB) and the Hong Kong Stock Exchange (09688.HK), with operational headquarters in Shanghai and Cambridge, Massachusetts. The company discovers, develops, manufactures, and commercializes innovative therapeutics for oncology, immunology, neuroscience, and infectious disease, serving patients and healthcare providers across Greater China with a growing global footprint in the US, Europe, and Asia Pacific.

Zai Lab operates an end-to-end model spanning internal discovery through commercial manufacturing, anchored by a proprietary pipeline that includes the lead DLL3-targeting antibody-drug conjugate zocilurtatug pelitecan (zoci), the IL-13/IL-31R bispecific ZL-1503, the LRRC15 ADC ZL-6201, and the PD-1/IL-12 immunocytokine ZL-1222. Eight products are approved in mainland China, including ZEJULA, OPTUNE GIO, QINLOCK, AUGTYRO, TIVDAK, VYVGART, NUZYRA, XACDURO, and COBENFY, with six on the National Reimbursement Drug List. Manufacturing capabilities include small-molecule facilities in Suzhou (20M hard capsules and 50M tablets annually) and a 4,200 sqm large-molecule facility with GE Flexfactory.

The business model combines in-licensed product commercialization in Greater China with proprietary global pipeline development, generating revenue through product sales supplemented by licensing and partnership arrangements with partners including argenx, Karuna/BMS, Seagen/Pfizer, Vertex, Blueprint Medicines, GSK, Regeneron, BMS, and Novocure. Distribution relies on a specialized disease-franchise commercial organization covering mainland China, Hong Kong, Macau, and Taiwan, with NRDL inclusion, patient assistance programs, and Named Patient Programs driving access. In FY2025, Zai Lab generated $460.2M in revenue (15% YoY growth) with a $175.5M net loss, supported by a $761.3M cash position as of Q1 2026 and approximately 2,100 employees globally.

Zai Lab firmographics

Firmographics
Name
Zai Lab
Legal name
Zai Lab Limited
Website
https://zailaboratory.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Zai Lab is a US-China biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative oncology, immunology, neuroscience, and infectious disease therapies for patients across Greater China and select global markets, with eight approved products and six on China's National Reimbursement Drug List.
Ownership category
akta.pro rank

Where Zai Lab is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices8 records

Markets served

Zai Lab business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Product Sales - Oncology: Sales of approved oncology products including ZEJULA (niraparib), OPTUNE GIO, QINLOCK (ripretinib), AUGTYRO (repotrectinib), and TIVDAK (tisotumab vedotin). Zai Lab currently has eight approved products in mainland China.
  2. Product Sales - Immunology: Sales of efgartigimod (VYVGART) for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP).
  3. Product Sales - Infectious Disease: Sales of NUZYRA (omadacycline) for CABP and ABSSSI, and XACDURO (sulbactam-durlobactam) for HABP/VABP.
  4. Product Sales - Neuroscience: Sales of COBENFY (xanomeline and trospium chloride) for schizophrenia following December 2025 NMPA approval.
  5. Licensing and Partnership Revenue: Revenue from licensing agreements with partners including Karuna Therapeutics for COBENFY in Greater China, Seagen/Pfizer for TIVDAK, and collaborations with global pharmaceutical companies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Zai Lab product offering

Product offering

Core offering

Zai Lab is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative therapeutics for oncology, immunology, neuroscience, and infectious diseases, with eight approved products currently marketed in mainland China and a global pipeline of proprietary candidates. The company combines in-licensed assets from partners such as argenx, Pfizer/Seagen, Karuna/BMS, and Novocure with internally developed antibody-drug conjugates and bispecifics to serve patients and healthcare providers primarily across Greater China, with growing global commercialization plans for the US, Europe, and Asia Pacific.

Differentiator

Problem solved

Functional benefit

Products and services

  • ZEJULA (niraparib) PARP inhibitor for first-line maintenance treatment and recurrent maintenance therapy of ovarian cancer, marketed in Greater China.
  • OPTUNE GIO (Tumor Treating Fields) Tumor Treating Fields delivery system for the treatment of newly diagnosed and recurrent glioblastoma, marketed in Greater China in partnership with Novocure.
  • QINLOCK (ripretinib) Tyrosine kinase inhibitor for fourth-line treatment of advanced gastrointestinal stromal tumors (GIST), marketed in mainland China.
  • AUGTYRO (repotrectinib) Tyrosine kinase inhibitor for the treatment of ROS1-positive non-small cell lung cancer (NSCLC) and NTRK-positive solid tumors, marketed in Greater China.
  • TIVDAK (tisotumab vedotin) Antibody-drug conjugate (tisotumab vedotin) for adult patients with recurrent or metastatic cervical cancer who have progressed on or after chemotherapy, marketed in Greater China under license from Seagen/Pfizer.
  • VYVGART (efgartigimod) FcRn antagonist (efgartigimod alfa) for adult patients with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), marketed in Greater China under partnership with argenx.
  • NUZYRA (omadacycline) Broad-spectrum antibiotic (omadacycline) for the treatment of community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI), marketed in mainland China.
  • XACDURO (sulbactam-durlobactam) Antibiotic combination (sulbactam-durlobactam) for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus complex, marketed in China.
  • COBENFY (xanomeline and trospium chloride) M1/M4 muscarinic receptor agonist combination (xanomeline and trospium chloride) for the treatment of schizophrenia in adults, marketed in Greater China under license from Karuna Therapeutics (Bristol-Myers Squibb).

Quantifiable outcome

  • 45% reduction in risk of death (HR: 0.55) in China subpopulation for TIVDAK vs chemotherapy in recurrent/metastatic cervical cancer
  • +4 more outcomes

Companies that use Zai Lab

Customer profile

Named customers2 records

Segments4 records

Ideal customer profiles3 records

Zai Lab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Zai Lab partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Boehringer IngelheimcoreStrategic or Co-development Partner · 15 April 2026Collaboration on DLL3-targeting T-cell engager and ADC combination in small cell lung cancer and other neuroendocrine carcinomas. The collaboration combines Zai Lab's zoci ADC with Boehringer Ingelheim's DLL3-targeting bispecific T-cell engager therapy.
  • AmgencoreStrategic or Co-development Partner · 1 April 2026Global clinical trial collaboration to evaluate Zai Lab's zocilurtatug pelitecan (DLL3-targeting ADC) in combination with Amgen's IMDELLTRA for extensive-stage small cell lung cancer. Amgen sponsors and leads the Phase 1b study while Zai Lab retains full ownership of its ADC and provides clinical supply.
  • VertexcoreStrategic or Co-development PartnerCollaboration on povetacicept (BAFF/APRIL) in IgA nephropathy. Zai Lab has exclusive license to develop and commercialize povetacicept in mainland China, Hong Kong, Macau, Taiwan, and Singapore.

Scale indicators10 records

Recent moves13 records

Expansion highlights6 records

Zai Lab competitors and assessment

Company assessment

Direct peers

  • BeiGene (now BeOne Medicines): China-founded, US-listed biopharmaceutical company with a similar business model combining a profitable China commercial organization (BRUKINSA, etc.) with a global innovation pipeline. Direct peer in oncology-focused biopharma bridging China and global markets.
  • HUTCHMED (China) Limited: China-founded, Hong Kong and NASDAQ-listed biopharma developing and commercializing oncology and immunology therapies in China and globally. Comparable in China-focused oncology R&D and commercialization, with overlapping NRDL-listed products and global out-licensing strategy.
  • Innovent Biologics: China-based biopharma with multiple approved and NRDL-included products in oncology (TYVYT/PD-1, etc.) and growing pipeline. Closely comparable in China commercialization scale, NRDL positioning, and dual China-US R&D footprint.
  • Akeso, Inc. China-based biopharma developing novel antibodies including PD-1/VEGF bispecifics, with growing commercialization in oncology and immunology. Comparable in novel biologics discovery, China NRDL access, and dual China/global development strategy.
  • Shanghai Junshi Biosciences: China-based biopharma with an approved PD-1 antibody (toripalimab) and broader oncology pipeline, dual-listed in Hong Kong and on STAR Market. Comparable as a China-headquartered immuno-oncology player with global ambitions.

Broad incumbents

  • Hengrui Medicine: China's largest domestic pharmaceutical company with broad oncology, immunology, and other therapeutic portfolios plus extensive NRDL presence. Comparable as a China commercial-scale pharma competitor but with a much broader, established portfolio and generic + innovative mix.
  • Hansoh Pharmaceutical Group: Large China-headquartered pharmaceutical company with multiple approved innovative drugs across oncology, CNS, and infectious disease. Comparable as a broad Chinese pharma operator with overlapping therapeutic categories and NRDL commercialization experience.
  • CSPC Pharmaceutical Group: Hong Kong-listed Chinese pharmaceutical conglomerate with oncology, neurology, and anti-infective product portfolios plus R&D pipeline. Comparable as a broad incumbent operating in Zai Lab's therapeutic categories and NRDL channels.

Others

  • Bristol-Myers Squibb: Global biopharma and existing Zai Lab partner/seller of in-licensed products (QINLOCK, AUGTYRO, COBENFY via Karuna acquisition). Comparable as a global oncology and immunology player with overlapping therapeutic franchises and pipeline interest in DLL3 and related targets.
  • Amgen: Global biopharma with the competing DLL3-targeted T-cell engager IMDELLTRA, and strategic clinical collaboration partner with Zai Lab on zoci + IMDELLTRA combinations. Comparable as a global oncology innovator with overlapping SCLC pipeline interests and partner-based China market access patterns.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Zai Lab social profiles

Digital presence

Zai Lab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Zai Lab leadership team

Management profile

Number of profiles

Profiles26 records

Zai Lab funding detail

Funding detail

Funding overview

Funding rounds14 records

Investors21 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Zai Lab M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zai Lab

What does Zai Lab do?

Zai Lab is a commercial-stage biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative therapeutics for oncology, immunology, neuroscience, and infectious diseases, with eight approved products currently marketed in mainland China and a global pipeline of proprietary candidates. The company combines in-licensed assets from partners such as argenx, Pfizer/Seagen, Karuna/BMS, and Novocure with internally developed antibody-drug conjugates and bispecifics to serve patients and healthcare providers primarily across Greater China, with growing global commercialization plans for the US, Europe, and Asia Pacific.

Is Zai Lab a public or private company?

Zai Lab is a public company. It is classified as public and is currently operating.

When was Zai Lab founded?

Zai Lab was founded in 2014. It employs 501 to 1,000 people.

Where is Zai Lab based?

Zai Lab is headquartered in Shanghai, China, in the Asia region.

How does Zai Lab make money?

Five revenue lines are on record. Product Sales - Oncology is the primary driver. The others are product Sales - Immunology, product Sales - Infectious Disease, product Sales - Neuroscience and licensing and Partnership Revenue.

Who are Zai Lab's main competitors?

Direct peers on record are BeiGene (now BeOne Medicines), HUTCHMED (China) Limited, Innovent Biologics, Akeso, Inc. and Shanghai Junshi Biosciences. Broad incumbents are Hengrui Medicine, Hansoh Pharmaceutical Group and CSPC Pharmaceutical Group. Others are Bristol-Myers Squibb and Amgen.

Does Zai Lab have an API?

No public API is recorded for Zai Lab.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Seeking AlphaZai Lab: Tarlatamab's First-Line Win Makes Zoci The DLL3 Partner Of ChoiceZai Lab's zoci, a DLL3 treatment, showed an 81.8% response rate in first-line data across 33 evaluable patients, with Amgen and Boehringer funding combination studies. The company expects product revenue growth to return in 2027, while DLLEVATE's 2027 interim analysis is a key risk.TradingViewZai Lab Limited Adds 2 Drugs to China's NRDLZai Lab said five commercial medicines in China were included in the 2026 NRDL, with KarXT and VYVGART Hytrulo as first-time listings and three others renewed. The list takes effect Jan. 1, 2027, with no prior-period comparison provided.FinancialContent Business PageZai Lab Announces First-Time Inclusion of KarXT and VYVGART Hytrulo® in China’s 2026 National Reimbursement Drug List, Expanding Access to Key Growth ProductsZai Lab announced that five of its commercial medicines were added to China's 2026 National Reimbursement Drug List, including two first-time listings: VYVGART Hytrulo for generalized myasthenia gravis and KarXT for schizophrenia. The list takes effect January 1, 2027, expanding access to these growth products.TradingViewZai Lab Limited Adds Two Products to China’s 2026 Reimbursement ListZai Lab's KarXT and VYVGART Hytrulo were added to China's 2026 National Reimbursement Drug List, with three other products renewed. The list takes effect January 1, 2027, and no revenue or pricing details were disclosed.BenzingaZai Lab Advances Atopic Dermatitis Candidate Toward Potential Quarterly Maintenance Dosing - Zai Lab (NASZai Lab reported preliminary results from its Phase 1/1b trial of ZL-1503, a bispecific antibody for atopic dermatitis. A single 200 mg dose inhibited STAT6 by at least 90% for 12 weeks, with a half-life of 40-50 days. The company expects Part B cohort data in the first half of 2027.Seeking AlphaZai Lab Limited (ZLAB) Discusses ZL-1503 Phase 1 Data and Atopic Dermatitis Development Plans TranscriptZai Lab's Rafael Amado presented Phase 1 data for ZL-1503, a bispecific antibody targeting IL-13 and IL-31, at the ACAAI meeting. The study met all objectives, and the program continues with atopic dermatitis trials, with MAD data expected in the first half of next year.TradingViewZai Lab: ZL-1503 showed sustained pathway inhibition and a 40-50-day half-life in Phase 1Zai Lab's ZL-1503 showed sustained IL-13 pathway inhibition and a 40-50-day half-life in healthy volunteers, with a favorable safety profile. AD patient and IV-to-SC bridging data are expected in the first half of 2027.Seeking AlphaZai Lab Limited 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:ZLAB) 2026-11-09Zai Lab Limited reported Q3 2026 EPS of -$0.41, beating by $0.11, but revenue of $108.21M missed by $229.45K. Revenue fell 6.79% year-over-year. The company's stock closed at $26.86, up 5.42%.Simply Wall StIs Zai Lab (ZLAB) A Bargain After New Trial Data And Fresh Funding?Zai Lab's share price rose 12.7% in one day after fresh Phase 1 data for its lead cancer drug, new funding, and Q3 2026 results. The stock is trading at $25.48, with an analyst fair value of $33.48, though product revenue fell 3.3% year on year to $105.8 million in Q2 2026.MoomooHong Kong Stock Market Update | Zai Lab (09688) Rises Over 10% Again; Q3 Product Revenue Reaches $107.6 Million; Global Clinical R&D for Zocci Achieves New ProgressZai Lab shares rose over 10% to HK$20.2, with Q3 product revenue reaching $107.6 million, up 2% quarter over quarter. The company expects to submit its first Biologics License Application for zoci in the US in 2027.